Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric Antigen Receptor (CAR) T-cell therapy shows promise for aggressive hematological malignancies but faces limitations with autologous product manufacturing, including quantity, quality, purity, cost, and logistics.
• These challenges render many patients ineligible for autologous CAR T-cell therapy, necessitating extensive genetic modifications to overcome biological, clinical, and manufacturing hurdles.

Purpose of the Study:

• To explore the potential of engineering "off-the-shelf" universal CAR T cells (UCART) as a safer, effective, and affordable alternative to conventional CAR T cells.
• To highlight the advantages of UCART therapy, including batch production, quality control, multiplex genetic modification, and reduced manufacturing time.
• To identify key areas for advancement in UCART therapy, such as mitigating graft-versus-host disease (GvHD) and graft rejection (GR), optimizing preparative chemotherapy, infection control, and CAR T-cell persistence.

Main Methods:

• Review of current CAR T-cell therapy limitations and the emerging strategies for universal CAR T-cell (UCART) engineering.
• Discussion of engineering strategies to overcome GvHD and GR, and to optimize supportive care and persistence.
• Exploration of innovations in inducible molecular switches, split CAR design, CRISPR/Cas9 gene targeting, rational subset composition, and cryopreservation for UCART development.

Main Results:

• UCART therapy enables batch production of a quality-controlled product with multiplex genetic modification in a shorter timeframe, addressing manufacturing challenges.
• Current UCART programs primarily target CD19, followed by BCMA and CD70, with ongoing research focused on engineering strategies to curb GvHD and GR.
• Innovations in inducible molecular switches, split CAR design, CRISPR/Cas9, subset composition, and cryopreservation are rapidly advancing UCART therapy development.

Conclusions:

• UCART therapy presents a viable, cost-effective, and scalable alternative to autologous CAR T-cell therapy for hematological malignancies.
• Further engineering strategies are crucial to address GvHD, GR, and optimize supportive care for successful clinical translation of UCART therapy.
• Advancements in CAR T-cell engineering technologies are accelerating the transition of UCART therapy from bench to bedside, offering improved therapeutic options.